Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesVeterinary Medicine

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1642246

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1642246

Veterinary Vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End user (Hospitals, Clinics) - Global Forecast to 2029

PUBLISHED:
PAGES: 407 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The veterinary vaccines market is projected to reach USD 13.33 billion by 2029, from USD 9.39 billion in 2024, at a CAGR of 6.1%." during the forecast period.

Scope of the Report
Years Considered for the Study2024-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy type, disease, technology, route of administration, end user
Regions coveredNorth America, Europe, APAC, LATAM, and MEA

The growing awareness of animal health, along with the rising pet population and pet ownership, is driving the adoption of veterinary vaccines. Government initiatives aimed at improving animal health and the increasing uptake of pet insurance policies are also contributing to this trend. In major markets like North America and Europe, many pet owners are purchasing pet insurance due to the significant rise in pet care spending in recent years. Additionally, the focus on developing new and advanced vaccine products, combined with the growing adoption of veterinary vaccines in emerging economies, is expected to further support market growth. However, the high costs associated with vaccines may pose a challenge to the veterinary vaccines market's expansion.

"The livestock vaccines segment of veterinary vaccines market to register highest share during the forecast period."

Based on type, the livestock vaccines segment accounted for the largest share. As livestock animals are owned for the production of food, such as meat and dairy products. As global demand for animal derived food increases and livestock farming intensifies to meet the nutritional needs of an expanding population, there is a greater emphasis on maintaining animal health, preventing disease outbreaks, and improving productivity. Additionally, government regulations, rising awareness about animal health, and growing demand for safer, disease-free food products are driving the adoption of livestock vaccines, further contributing to their dominant share in the market.

"The intramuscular segment to capture the largest market share of veterinary vaccines market."

Based on route of administration, intramuscular vaccines hold a higher share in the veterinary vaccines market due to their effectiveness and widespread use. Compared to conventional methods of administration like subcutaneous or oral vaccines, this kind of vaccine is delivered directly into the muscle, enabling a faster and more powerful immune response. Because of their ability to produce long-lasting immunity, intramuscular vaccines are frequently used to treat a range of conditions, including bacterial, viral, and parasite infections. The increased market share of intramuscular vaccines is partly a result of their shown efficacy, simplicity of use, and veterinarians' inclination for this approach in both individual pet care and large-scale farming.

"Asia pacific accounted for the fastest growing region of the veterinary vaccines market by region."

The global veterinary vaccines market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing market for veterinary vaccines. The increased ownership of pets is a major factor driving the need for veterinary care and vaccinations, particularly in economies like China, India, and Japan. Pet owners are also being encouraged to invest in vaccinations as a result of the region's increasing awareness of animal health and preventative measures. Growing focus on livestock health, better veterinary facilities, and economic expansion all contribute significantly to the market's growth. Governments and organizations have backed animal health initiatives, and more consumers are looking for improved pet healthcare as disposable incomes rise. The Asia Pacific region is becoming a significant growth engine for the veterinary vaccines market due to this confluence of variables.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3- 25%
  • By Designation: Directors-25%, Managers-50% and Others-25%
  • By Region: North America-35%, Europe-30%, Asia Pacific-15% and RoW-20%

The major players operating in the veterinary vaccines market market are Zoetis(US), Merck & Co, Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), Biogenesis Bago (Argentina), Tianjin Ringpu BioTechnology Co., Ltd. (China), China Animal Husbandry Industry Co., LTD. (China), Jinyu Bio-technology Co., Ltd. (China), and Vaxxinova International B.V.(Netherlands).

Research Coverage

This report studies the veterinary vaccines market based on type, disease, technology, route of administration and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Analysis of Key divers (increased companion animal population and pet ownership, growing incidence of infectious disease, government initiatives to improve animal health), restraints (high cost associated with vaccines), Opportunities (emerging markets, technological advancement and developments) , Challenge (limited awareness and shortage of veterinarians, stringent regulatory requirements)
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the veterinary vaccines market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the veterinary vaccines market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the veterinary vaccines market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Show more
Product Code: PH 3475

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary sources
      • 2.1.1.2 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key primary sources
      • 2.1.2.2 Objectives of primary research
      • 2.1.2.3 Key data from primary sources
      • 2.1.2.4 Key industry insights
      • 2.1.2.5 Breakdown of primaries
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS)
    • 2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
    • 2.2.3 TOP-DOWN APPROACH
  • 2.3 DATA TRIANGULATION
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 RESEARCH LIMITATIONS
    • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 VETERINARY VACCINES MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)
  • 4.3 VETERINARY VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rise in companion animal population and pet ownership
      • 5.2.1.2 Increasing incidence of infectious zoonotic diseases
      • 5.2.1.3 Favorable initiatives by government agencies and animal associations
      • 5.2.1.4 Growing demand for animal-derived food products
      • 5.2.1.5 Increased adoption of pet insurance and high animal health expenditure
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of vaccine development
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Technological advancements for veterinary vaccine development
      • 5.2.3.2 Untapped growth potential in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limited awareness about animal vaccines and shortage of trained veterinarians in low-income countries
      • 5.2.4.2 Stringent regulatory requirements for licensing veterinary vaccines
  • 5.3 INDUSTRY TRENDS
  • 5.4 TECHNOLOGY ANALYSIS
    • 5.4.1 KEY TECHNOLOGIES
      • 5.4.1.1 Recombinant DNA technology
      • 5.4.1.2 mRNA-based vaccines
    • 5.4.2 COMPLEMENTARY TECHNOLOGIES
      • 5.4.2.1 Vaccine adjuvant technology
      • 5.4.2.2 Needle-free and microneedle technology
    • 5.4.3 ADJACENT TECHNOLOGIES
      • 5.4.3.1 Genome editing technology
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 VALUE CHAIN ANALYSIS
  • 5.8 TRADE ANALYSIS
    • 5.8.1 IMPORT DATA FOR HS CODE 300242
    • 5.8.2 EXPORT DATA FOR HS CODE 300230
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.10.2 KEY BUYING CRITERIA
  • 5.11 REGULATORY ANALYSIS
    • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.11.2 REGULATORY FRAMEWORK
      • 5.11.2.1 North America
        • 5.11.2.1.1 US
      • 5.11.2.2 Europe
      • 5.11.2.3 Rest of the World
        • 5.11.2.3.1 China
        • 5.11.2.3.2 Brazil
        • 5.11.2.3.3 Australia
  • 5.12 PATENT ANALYSIS
    • 5.12.1 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.13 PRICING ANALYSIS
    • 5.13.1 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2021-2023
    • 5.13.2 AVERAGE SELLING PRICE TREND, BY REGION, 2021-2023
  • 5.14 KEY CONFERENCES & EVENTS, 2024-2026
  • 5.15 ECOSYSTEM ANALYSIS
  • 5.16 CASE STUDY ANALYSIS
  • 5.17 REIMBURSEMENT ANALYSIS
  • 5.18 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.19 IMPACT OF AI/GEN AI ON VETERINARY VACCINES MARKET
  • 5.20 INVESTMENT & FUNDING SCENARIO
  • 5.21 PIPELINE ANALYSIS

6 VETERINARY VACCINES MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 LIVESTOCK VACCINES
    • 6.2.1 BOVINE VACCINES
      • 6.2.1.1 Increasing demand for meat and milk to drive market
    • 6.2.2 SMALL RUMINANT VACCINES
      • 6.2.2.1 Increased livestock population and favorable government initiatives to propel market growth
  • 6.3 PORCINE VACCINES
    • 6.3.1 GROWING AWARENESS ABOUT ANIMAL VACCINATION TO SUPPORT MARKET GROWTH
  • 6.4 POULTRY VACCINES
    • 6.4.1 HIGH NEED FOR PROTEIN IN DAILY DIET TO AUGMENT MARKET GROWTH
  • 6.5 COMPANION ANIMAL VACCINES
    • 6.5.1 CANINE VACCINES
      • 6.5.1.1 Increasing number of pet dogs and growing prevalence of zoonotic diseases to spur market growth
    • 6.5.2 FELINE VACCINES
      • 6.5.2.1 Rising adoption of cats and growing need for better veterinary care to boost market growth
  • 6.6 AQUACULTURE VACCINES
    • 6.6.1 INCREASED POPULARITY OF COMMERCIAL FISH FARMING TO FUEL MARKET GROWTH
  • 6.7 OTHER VETERINARY VACCINES

7 VETERINARY VACCINES MARKET, BY DISEASE

  • 7.1 INTRODUCTION
  • 7.2 LIVESTOCK DISEASES
    • 7.2.1 BOVINE DISEASES
      • 7.2.1.1 Favorable government programs and increased awareness about animal health in emerging economies to aid market growth
    • 7.2.2 SMALL RUMINANT DISEASES
      • 7.2.2.1 New vaccine formulations and improved delivery methods to propel vaccine demand for small ruminants
  • 7.3 PORCINE DISEASES
    • 7.3.1 INCREASED FOCUS ON LARGE-SCALE INDUSTRIAL BREEDING OF PIGS TO AID MARKET GROWTH
  • 7.4 POULTRY DISEASES
    • 7.4.1 ONGOING RISK OF AVIAN INFLUENZA OUTBREAKS TO SPUR NEED FOR POULTRY VACCINES
  • 7.5 COMPANION ANIMAL DISEASES
    • 7.5.1 CANINE DISEASES
      • 7.5.1.1 Rise in pet ownership in emerging economies to boost market growth
    • 7.5.2 FELINE DISEASES
      • 7.5.2.1 Rise in cat population in urban areas to drive demand for feline disease management programs
  • 7.6 AQUACULTURE DISEASES
    • 7.6.1 NEED FOR PREVENTIVE HEALTHCARE AND BIOSECURITY TO SUPPORT MARKET GROWTH
  • 7.7 OTHER VETERINARY DISEASES

8 VETERINARY VACCINES MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
  • 8.2 LIVE ATTENUATED VACCINES
    • 8.2.1 EASE OF ADMINISTRATION AND LONG-TERM IMMUNITY TO SUPPORT MARKET GROWTH
  • 8.3 INACTIVATED VACCINES
    • 8.3.1 NEED TO DEVELOP ARTIFICIAL IMMUNITY FROM NON-LIVING PATHOGENS TO DRIVE MARKET
  • 8.4 TOXOID VACCINES
    • 8.4.1 TOXOID VACCINES TO STIMULATE IMMUNE SYSTEM AND PROTECT ANIMALS FROM BACTERIAL TOXINS
  • 8.5 RECOMBINANT VACCINES
    • 8.5.1 BETTER STABILITY, HIGHER SAFETY, AND NO POST-VACCINATION REACTIONS TO SUPPORT VACCINE ADOPTION
  • 8.6 OTHER VACCINE TECHNOLOGIES

9 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
  • 9.2 SUBCUTANEOUS ROUTE OF ADMINISTRATION
    • 9.2.1 EASE OF ADMINISTRATION, REDUCED PAIN, AND LOWER RISK OF TISSUE DAMAGE TO AID MARKET GROWTH
  • 9.3 INTRAMUSCULAR ROUTE OF ADMINISTRATION
    • 9.3.1 BETTER IMMUNE RESPONSE AND LOWER RATE OF INJECTION-SITE REACTIONS TO AUGMENT MARKET GROWTH
  • 9.4 ORAL ROUTE OF ADMINISTRATION
    • 9.4.1 COST-EFFECTIVENESS, INCREASED SAFETY, AND HIGH PATIENT ACCEPTABILITY TO SUPPORT MARKET GROWTH
  • 9.5 INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
    • 9.5.1 COST-EFFECTIVENESS AND RAPID ABSORPTION OF MEDICINE TO AID IN MASS VACCINATION
  • 9.6 INTRAOCULAR ROUTE OF ADMINISTRATION
    • 9.6.1 SIMPLE ADMINISTRATION OF VACCINES IN LARGE-SCALE FARMING OPERATIONS TO AID MARKET GROWTH
  • 9.7 OTHER ROUTES OF ADMINISTRATION

10 VETERINARY VACCINES MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 VETERINARY HOSPITALS
    • 10.2.1 GROWING AWARENESS ABOUT ANIMAL HEALTH AND INCREASING VETERINARY EXPENDITURE BY PET OWNERS TO DRIVE MARKET
  • 10.3 VETERINARY CLINICS
    • 10.3.1 RISING NUMBER OF PET VISITS TO PRIVATE CLINICS TO SPUR MARKET GROWTH
  • 10.4 OTHER END USERS

11 VETERINARY VACCINES MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 ASIA PACIFIC
    • 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 11.2.2 CHINA
      • 11.2.2.1 Increasing companion animal population and growing incidence of zoonotic diseases to drive market
    • 11.2.3 JAPAN
      • 11.2.3.1 High consumption of animal-derived products and increased pet health expenditure to propel market growth
    • 11.2.4 INDIA
      • 11.2.4.1 Growth in poultry industry and high demand for dairy products to augment market growth
    • 11.2.5 AUSTRALIA
      • 11.2.5.1 Increase in per capita income and rise in meat consumption to aid market growth
    • 11.2.6 SOUTH KOREA
      • 11.2.6.1 High demand for animal protein and favorable government subsidies for meat production to spur market growth
    • 11.2.7 NEW ZEALAND
      • 11.2.7.1 Favorable government initiatives and increased incidence of livestock diseases to boost market growth
    • 11.2.8 REST OF ASIA PACIFIC
  • 11.3 NORTH AMERICA
    • 11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 11.3.2 US
      • 11.3.2.1 US to dominate North American veterinary vaccines market during forecast period
    • 11.3.3 CANADA
      • 11.3.3.1 Rising pet ownership and increasing chicken consumption to drive demand for veterinary vaccines
  • 11.4 EUROPE
    • 11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 11.4.2 GERMANY
      • 11.4.2.1 Increased poultry consumption and high pet healthcare expenditure to drive market
    • 11.4.3 UK
      • 11.4.3.1 Rising adoption of pets to augment market growth
    • 11.4.4 FRANCE
      • 11.4.4.1 Rising companion animal and livestock population to boost market growth
    • 11.4.5 ITALY
      • 11.4.5.1 Better availability of pet products through large-scale outlets to augment market growth
    • 11.4.6 SPAIN
      • 11.4.6.1 Increase in veterinary practices and willingness to spend on animal healthcare to drive market
    • 11.4.7 NETHERLANDS
      • 11.4.7.1 High demand for meat and increased pressure on sustainable farming practices to fuel market growth
    • 11.4.8 REST OF EUROPE
  • 11.5 LATIN AMERICA
    • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 11.5.2 BRAZIL
      • 11.5.2.1 Well-established livestock industry to promote market growth
    • 11.5.3 MEXICO
      • 11.5.3.1 Focus on pork and poultry meat production to fuel market growth
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Kingdom of Saudi Arabia
        • 11.6.2.1.1 Favorable government initiatives for better animal health infrastructure to propel market growth
      • 11.6.2.2 UAE
        • 11.6.2.2.1 Favorable government initiatives to safeguard national livestock population and support sustainable agriculture
      • 11.6.2.3 Rest of GCC countries
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE ANALYSIS, 2019-2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
    • 12.4.1 RANKING OF KEY MARKET PLAYERS, 2O23
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Type footprint
      • 12.5.5.4 Disease footprint
      • 12.5.5.5 Technology footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 BRAND/PRODUCT COMPARISON
  • 12.8 R&D EXPENDITURE OF KEY PLAYERS
  • 12.9 COMPANY VALUATION & FINANCIAL METRICS
    • 12.9.1 FINANCIAL METRICS
    • 12.9.2 COMPANY VALUATION
  • 12.10 COMPETITIVE SCENARIO
    • 12.10.1 PRODUCT LAUNCHES & APPROVALS
    • 12.10.2 DEALS
    • 12.10.3 EXPANSIONS
    • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 MERCK & CO., INC.
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches & approvals
        • 13.1.1.3.2 Deals
        • 13.1.1.3.3 Expansions
        • 13.1.1.3.4 Other developments
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 ZOETIS
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product launches
        • 13.1.2.3.2 Deals
        • 13.1.2.3.3 Expansions
        • 13.1.2.3.4 Other developments
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches
        • 13.1.3.3.2 Expansions
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 ELANCO
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
    • 13.1.5 CEVA
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Deals
        • 13.1.5.3.2 Expansions
    • 13.1.6 VIRBAC
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product launches
        • 13.1.6.3.2 Deals
        • 13.1.6.3.3 Expansions
        • 13.1.6.3.4 Other developments
    • 13.1.7 PHIBRO ANIMAL HEALTH CORPORATION
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
    • 13.1.8 HESTER BIOSCIENCES LIMITED
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Deals
    • 13.1.9 NEOGEN CORPORATION
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Deals
    • 13.1.10 HIPRA
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Recent developments
        • 13.1.10.3.1 Product launches
    • 13.1.11 BIOGENESIS BAGO
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Expansions
    • 13.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Deals
    • 13.1.13 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
    • 13.1.14 JINYU BIO-TECHNOLOGY CO., LTD.
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Product approvals
    • 13.1.15 VAXXINOVA INTERNATIONAL B.V.
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product approvals
        • 13.1.15.3.2 Expansions
  • 13.2 OTHER COMPANIES
    • 13.2.1 ENDOVAC ANIMAL HEALTH
    • 13.2.2 BRILLIANT BIO PHARMA
    • 13.2.3 APTIMMUNE
    • 13.2.4 INDIAN IMMUNOLOGICALS LTD.
    • 13.2.5 TORIGEN PHARMACEUTICALS INC.
    • 13.2.6 INTAS PHARMACEUTICALS LTD.
    • 13.2.7 OUROFINO ANIMAL HEALTH
    • 13.2.8 BIOVAC LTD.
    • 13.2.9 LABORATOIRE LCV
    • 13.2.10 KYORITSU SEIYAKU CORPORATION

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Show more
Product Code: PH 3475

List of Tables

  • TABLE 1 VETERINARY VACCINES MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 STANDARD CURRENCY CONVERSION RATES
  • TABLE 3 VETERINARY VACCINES MARKET: STUDY ASSUMPTIONS
  • TABLE 4 VETERINARY VACCINES MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 5 PET (DOGS AND CATS) OWNERSHIP IN US, 2024
  • TABLE 6 MAJOR OUTBREAKS OF ZOONOTIC DISEASES, 2022-2023
  • TABLE 7 PAST AND PROJECTED TRENDS IN CONSUMPTION OF MEAT AND MILK IN DEVELOPED COUNTRIES
  • TABLE 8 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 9 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 10 KEY COMMERCIAL PRODUCTS USING RECOMBINANT DNA TECHNOLOGY
  • TABLE 11 IMPORT DATA FOR HS CODE 300230, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 12 EXPORT VALUE FOR HS CODE 300230, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 13 VETERINARY VACCINES MARKET: PORTER'S FIVE FORCES
  • TABLE 14 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF VETERINARY VACCINES, BY END USER
  • TABLE 15 KEY BUYING CRITERIA FOR END USERS
  • TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 VETERINARY VACCINES MARKET: LIST OF GRANTED PATENTS, 2022-2023
  • TABLE 20 AVERAGE SELLING PRICE TREND OF VETERINARY VACCINES, BY KEY PLAYER, 2021-2023
  • TABLE 21 AVERAGE SELLING PRICE TREND OF CANINE VACCINES (PER DOSE), BY REGION, 2021-2023
  • TABLE 22 AVERAGE SELLING PRICE TREND OF LIVESTOCK VACCINES (PER DOSE) BY REGION, 2021-2023
  • TABLE 23 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2026
  • TABLE 24 VETERINARY VACCINES MARKET: ROLE IN ECOSYSTEM
  • TABLE 25 CASE STUDY 1: SUPPORTING INNOVATION IN LIVESTOCK VACCINES
  • TABLE 26 CASE STUDY 2: IMPACT OF A19 VACCINATION ON LIVESTOCK HEALTH AND PRODUCTIVITY
  • TABLE 27 CASE STUDY 3: DEVELOPMENT OF CANINE VACCINES FOR VALLEY FEVER
  • TABLE 28 VETERINARY VACCINES MARKET: UNMET NEEDS/END-USER EXPECTATIONS
  • TABLE 29 VETERINARY VACCINES MARKET: PIPELINE ANALYSIS
  • TABLE 30 VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 31 LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 32 LIVESTOCK VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 COMMERCIAL BOVINE VACCINES BY KEY MANUFACTURERS
  • TABLE 34 BOVINE VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 COMMERCIAL SMALL RUMINANT VACCINES BY KEY MANUFACTURERS
  • TABLE 36 SMALL RUMINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 COMMERCIAL PORCINE VACCINES BY KEY MANUFACTURERS
  • TABLE 38 PORCINE VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 COMMERCIAL POULTRY VACCINES BY KEY MANUFACTURERS
  • TABLE 40 POULTRY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 41 COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 42 COMPANION ANIMAL VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 COMMERCIAL CANINE VACCINES BY KEY MANUFACTURERS
  • TABLE 44 CANINE VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 COMMERCIAL FELINE VACCINES BY KEY MANUFACTURERS
  • TABLE 46 FELINE VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 COMMERCIAL AQUACULTURE VACCINES BY KEY MANUFACTURERS
  • TABLE 48 AQUACULTURE VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 OTHER COMMERCIAL VETERINARY VACCINES BY KEY MANUFACTURERS
  • TABLE 50 OTHER VETERINARY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 52 VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 53 VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 BOVINE DISEASES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 SMALL RUMINANT DISEASES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 VETERINARY VACCINES MARKET FOR PORCINE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 VETERINARY VACCINES MARKET FOR POULTRY DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 59 VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 CANINE DISEASES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 FELINE DISEASES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 VETERINARY VACCINES MARKET FOR AQUACULTURE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 VETERINARY VACCINES MARKET FOR OTHER VETERINARY DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 65 COMMERCIALLY AVAILABLE KEY LIVE ATTENUATED VACCINES
  • TABLE 66 LIVE ATTENUATED VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 COMMERCIALLY AVAILABLE KEY INACTIVATED VACCINES
  • TABLE 68 INACTIVATED VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 COMMERCIALLY AVAILABLE KEY TOXOID VACCINES
  • TABLE 70 TOXOID VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 COMMERCIALLY AVAILABLE KEY RECOMBINANT VACCINES
  • TABLE 72 RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 COMMERCIALLY AVAILABLE OTHER KEY VACCINE TECHNOLOGIES
  • TABLE 74 OTHER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 ROUTES OF ADMINISTRATION FOR MAJOR VETERINARY VACCINES, BY KEY PLAYER
  • TABLE 76 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 77 COMMERCIALLY AVAILABLE VACCINES WITH SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • TABLE 78 VETERINARY VACCINES MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 COMMERCIALLY AVAILABLE VACCINES WITH INTRAMUSCULAR ROUTE OF ADMINISTRATION
  • TABLE 80 VETERINARY VACCINES MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 COMMERCIALLY AVAILABLE VACCINES WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 82 VETERINARY VACCINES MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 COMMERCIALLY AVAILABLE VACCINES WITH INTRANASAL/SPRAY ROUTE OF ADMINISTRATION
  • TABLE 84 VETERINARY VACCINES MARKET FOR INTRANASAL/SPRAY ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 85 COMMERCIALLY AVAILABLE VACCINES WITH INTRAOCULAR ROUTE OF ADMINISTRATION
  • TABLE 86 VETERINARY VACCINES MARKET FOR INTRAOCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 COMMERCIALLY AVAILABLE VACCINES WITH OTHER ROUTES OF ADMINISTRATION
  • TABLE 88 VETERINARY VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 90 VETERINARY HOSPITALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 91 VETERINARY CLINICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 92 OTHER END USERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 VETERINARY VACCINES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 94 PORCINE VACCINES MARKET, BY REGION, 2022-2029 (MILLION UNITS)
  • TABLE 95 POULTRY VACCINES MARKET, BY REGION, 2022-2029 (MILLION UNITS)
  • TABLE 96 BOVINE VACCINES MARKET, BY REGION, 2022-2029 (MILLION UNITS)
  • TABLE 97 SMALL RUMINANT VACCINES MARKET, BY REGION, 2022-2029 (MILLION UNITS)
  • TABLE 98 CANINE VACCINES MARKET, BY REGION, 2022-2029 (MILLION UNITS)
  • TABLE 99 FELINE VACCINES MARKET, BY REGION, 2022-2029 (MILLION UNITS)
  • TABLE 100 AQUACULTURE VACCINES MARKET, BY REGION, 2022-2029 (MILLION UNITS)
  • TABLE 101 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 111 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 113 NUMBER OF VETERINARIANS IN KEY ASIA PACIFIC COUNTRIES, 2022
  • TABLE 114 CHINA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 115 CHINA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 116 CHINA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 117 CHINA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 118 CHINA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 CHINA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 120 CHINA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 121 CHINA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 122 CHINA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 123 JAPAN: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 124 JAPAN: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 125 JAPAN: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 126 JAPAN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 127 JAPAN: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 128 JAPAN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 129 JAPAN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 130 JAPAN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 131 JAPAN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 132 JAPAN: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 133 INDIA: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS)
  • TABLE 134 INDIA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 135 INDIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 136 INDIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 137 INDIA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 138 INDIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 139 INDIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 140 INDIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 141 INDIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 142 INDIA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 143 AUSTRALIA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 144 AUSTRALIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 145 AUSTRALIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 146 AUSTRALIA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 147 AUSTRALIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 148 AUSTRALIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 AUSTRALIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 150 AUSTRALIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 151 AUSTRALIA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 152 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 153 SOUTH KOREA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 SOUTH KOREA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 SOUTH KOREA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 156 SOUTH KOREA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 157 SOUTH KOREA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 SOUTH KOREA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 159 SOUTH KOREA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 160 SOUTH KOREA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 161 NEW ZEALAND: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 162 NEW ZEALAND: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 163 NEW ZEALAND: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 164 NEW ZEALAND: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 165 NEW ZEALAND: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 166 NEW ZEALAND: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 167 NEW ZEALAND: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 168 NEW ZEALAND: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 169 NEW ZEALAND: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 170 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 REST OF ASIA PACIFIC: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 REST OF ASIA PACIFIC: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 174 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 175 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 176 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 177 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 178 REST OF ASIA PACIFIC: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 179 NORTH AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 180 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 NORTH AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 NORTH AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 183 NORTH AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 184 NORTH AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 185 NORTH AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 186 NORTH AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 187 NORTH AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 188 NORTH AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 189 NUMBER OF VETERINARIANS IN US AND CANADA, 2022
  • TABLE 190 PET INDUSTRY EXPENDITURE IN US, 2018-2024 (USD BILLION)
  • TABLE 191 US: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 192 US: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 193 US: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 194 US: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 195 US: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 US: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 US: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 198 US: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 199 US: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 200 CANADA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 201 CANADA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 202 CANADA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 203 CANADA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 204 CANADA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 205 CANADA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 206 CANADA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 207 CANADA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 208 CANADA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 209 EUROPE: VETERINARY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 210 EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 211 EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 212 EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 213 EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 214 EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 215 EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 216 EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 217 EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 218 EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 219 NUMBER OF VETERINARIANS IN EUROPE, 2022
  • TABLE 220 GERMANY: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 221 GERMANY: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 222 GERMANY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 223 GERMANY: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 224 GERMANY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 225 GERMANY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 226 GERMANY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 227 GERMANY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 228 GERMANY: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 229 PET POPULATION IN UK, 2024
  • TABLE 230 UK: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 UK: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 232 UK: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 233 UK: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 234 UK: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 235 UK: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 236 UK: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 237 UK: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 238 UK: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 239 FRANCE: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 240 FRANCE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 241 FRANCE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 FRANCE: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 243 FRANCE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 244 FRANCE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 245 FRANCE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 246 FRANCE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 247 FRANCE: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 248 ITALY: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 249 ITALY: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 250 ITALY: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 251 ITALY: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 252 ITALY: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 ITALY: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 254 ITALY: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 255 ITALY: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 256 ITALY: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 257 SPAIN: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 258 SPAIN: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 259 SPAIN: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 SPAIN: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 261 SPAIN: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 262 SPAIN: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 263 SPAIN: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 264 SPAIN: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 265 SPAIN: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 266 NETHERLANDS: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 NETHERLANDS: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 268 NETHERLANDS: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 269 NETHERLANDS: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 270 NETHERLANDS: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 271 NETHERLANDS: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 272 NETHERLANDS: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 273 NETHERLANDS: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 274 NETHERLANDS: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 275 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 REST OF EUROPE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 277 REST OF EUROPE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 278 REST OF EUROPE: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 279 REST OF EUROPE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 280 REST OF EUROPE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 REST OF EUROPE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 282 REST OF EUROPE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 283 REST OF EUROPE: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 284 LATIN AMERICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 285 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 287 LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 288 LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 289 LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 290 LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 291 LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 292 LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 293 LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 294 BRAZIL: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 295 BRAZIL: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 296 BRAZIL: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 297 BRAZIL: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 298 BRAZIL: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 299 BRAZIL: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 BRAZIL: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 301 BRAZIL: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 302 BRAZIL: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 303 MEXICO: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 MEXICO: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 305 MEXICO: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 306 MEXICO: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 307 MEXICO: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 MEXICO: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 309 MEXICO: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 310 MEXICO: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 311 MEXICO: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 312 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 313 REST OF LATIN AMERICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 314 REST OF LATIN AMERICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 315 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 316 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 318 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 319 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 320 REST OF LATIN AMERICA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 321 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 322 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 323 MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 324 MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 325 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 326 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 327 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 328 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 329 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 330 MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 331 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 332 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 333 GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 334 GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 335 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 336 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 337 GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 338 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 339 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 340 GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 341 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 342 KINGDOM OF SAUDI ARABIA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 343 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 344 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 345 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 346 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 347 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 348 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 349 KINGDOM OF SAUDI ARABIA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 350 UAE: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 351 UAE: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 352 UAE: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 353 UAE: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 354 UAE: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 355 UAE: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 356 UAE: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 357 UAE: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 358 UAE: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 359 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 360 REST OF GCC COUNTRIES: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 361 REST OF GCC COUNTRIES: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 362 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 363 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 364 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 365 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 366 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 367 REST OF GCC COUNTRIES: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 368 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 369 REST OF MIDDLE EAST & AFRICA: LIVESTOCK VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 370 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL VACCINES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 371 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY DISEASE, 2022-2029 (USD MILLION)
  • TABLE 372 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR LIVESTOCK DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 373 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET FOR COMPANION ANIMAL DISEASES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 REST OF MIDDLE EAST & AFRICA VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 375 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 376 REST OF MIDDLE EAST & AFRICA: VETERINARY VACCINES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 377 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY VACCINES MARKET
  • TABLE 378 VETERINARY VACCINES MARKET: DEGREE OF COMPETITION
  • TABLE 379 VETERINARY VACCINES MARKET: REGION FOOTPRINT
  • TABLE 380 VETERINARY VACCINES MARKET: TYPE FOOTPRINT
  • TABLE 381 VETERINARY VACCINES MARKET: DISEASE FOOTPRINT
  • TABLE 382 VETERINARY VACCINES MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 383 VETERINARY VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 384 VETERINARY VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 385 VETERINARY VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 386 VETERINARY VACCINES MARKET: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 387 VETERINARY VACCINES MARKET: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 388 VETERINARY VACCINES MARKET: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024
  • TABLE 389 MERCK & CO., INC.: COMPANY OVERVIEW
  • TABLE 390 MERCK & CO., INC.: PRODUCTS OFFERED
  • TABLE 391 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 392 MERCK & CO., INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 393 MERCK & CO., INC.: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 394 MERCK & CO., INC.: OTHER DEVELOPMENTS, JANUARY 2021- DECEMBER 2024
  • TABLE 395 ZOETIS: COMPANY OVERVIEW
  • TABLE 396 ZOETIS: PRODUCTS OFFERED
  • TABLE 397 ZOETIS: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 398 ZOETIS: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 399 ZOETIS: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 400 ZOETIS: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024
  • TABLE 401 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 402 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
  • TABLE 403 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 404 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 405 ELANCO: COMPANY OVERVIEW
  • TABLE 406 ELANCO: PRODUCTS OFFERED
  • TABLE 407 ELANCO: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 408 CEVA: COMPANY OVERVIEW
  • TABLE 409 CEVA: PRODUCTS OFFERED
  • TABLE 410 CEVA: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 411 CEVA: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 412 VIRBAC: COMPANY OVERVIEW
  • TABLE 413 VIRBAC: PRODUCTS OFFERED
  • TABLE 414 VIRBAC: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 415 VIRBAC: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 416 VIRBAC: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 417 VIRBAC: OTHER DEVELOPMENTS, JANUARY 2021-DECEMBER 2024
  • TABLE 418 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY OVERVIEW
  • TABLE 419 PHIBRO ANIMAL HEALTH CORPORATION: PRODUCTS OFFERED
  • TABLE 420 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW
  • TABLE 421 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED
  • TABLE 422 HESTER BIOSCIENCES LIMITED: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 423 NEOGEN CORPORATION: COMPANY OVERVIEW
  • TABLE 424 NEOGEN CORPORATION: PRODUCTS OFFERED
  • TABLE 425 NEOGEN CORPORATION: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 426 HIPRA: COMPANY OVERVIEW
  • TABLE 427 HIPRA: PRODUCTS OFFERED
  • TABLE 428 HIPRA: PRODUCT LAUNCHES, JANUARY 2021-DECEMBER 2024
  • TABLE 429 BIOGENESIS BAGO: COMPANY OVERVIEW
  • TABLE 430 BIOGENESIS BAGO: PRODUCTS OFFERED
  • TABLE 431 BIOGENESIS BAGO: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 432 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 433 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 434 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: DEALS, JANUARY 2021- DECEMBER 2024
  • TABLE 435 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: COMPANY OVERVIEW
  • TABLE 436 CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.: PRODUCTS OFFERED
  • TABLE 437 JINYU BIO-TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 438 JINYU BIO-TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 439 JINYU BIO-TECHNOLOGY CO., LTD.: PRODUCT APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 440 VAXXINOVA INTERNATIONAL B.V.: COMPANY OVERVIEW
  • TABLE 441 VAXXINOVA INTERNATIONAL B.V.: PRODUCTS OFFERED
  • TABLE 442 VAXXINOVA INTERNATIONAL B.V.: PRODUCT APPROVALS, JANUARY 2021-DECEMBER 2024
  • TABLE 443 VAXXINOVA INTERNATIONAL B.V.: EXPANSIONS, JANUARY 2021-DECEMBER 2024
  • TABLE 444 ENDOVAC ANIMAL HEALTH: COMPANY OVERVIEW
  • TABLE 445 BRILLIANT BIO PHARMA: COMPANY OVERVIEW
  • TABLE 446 APTIMMUNE: COMPANY OVERVIEW
  • TABLE 447 INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW
  • TABLE 448 TORIGEN PHARMACEUTICALS INC.: COMPANY OVERVIEW
  • TABLE 449 INTAS PHARMACEUTICALS LTD.: COMPANY OVERVIEW
  • TABLE 450 OUROFINO ANIMAL HEALTH: COMPANY OVERVIEW
  • TABLE 451 BIOVAC LTD.: COMPANY OVERVIEW
  • TABLE 452 LABORATOIRE LCV: COMPANY OVERVIEW
  • TABLE 453 KYORITSU SEIYAKU CORPORATION: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 VETERINARY VACCINES MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
  • FIGURE 2 VETERINARY VACCINES MARKET: YEARS CONSIDERED
  • FIGURE 3 VETERINARY VACCINES MARKET: RESEARCH DESIGN
  • FIGURE 4 VETERINARY VACCINES MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 VETERINARY VACCINES MARKET: KEY PRIMARY SOURCES
  • FIGURE 6 VETERINARY VACCINES MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 7 VETERINARY VACCINES MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 9 BREAKDOWN OF PRIMARIES (SUPPLY-SIDE PARTICIPANTS): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 10 BREAKDOWN OF PRIMARIES (DEMAND-SIDE PARTICIPANTS): BY END USER, DESIGNATION, AND REGION
  • FIGURE 11 VETERINARY VACCINES MARKET: SUPPLY-SIDE MARKET SIZE ESTIMATION PROCESS
  • FIGURE 12 VETERINARY VACCINES MARKET: REVENUE SHARE ILLUSTRATION FOR ZOETIS (2023)
  • FIGURE 13 VETERINARY VACCINES MARKET: TOTAL REVENUE ANALYSIS (2023)
  • FIGURE 14 VETERINARY VACCINES MARKET: CAGR PROJECTION FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
  • FIGURE 16 VETERINARY VACCINES MARKET: TOP-DOWN APPROACH
  • FIGURE 17 VETERINARY VACCINES MARKET: DATA TRIANGULATION
  • FIGURE 18 VETERINARY VACCINES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 VETERINARY VACCINES MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 20 VETERINARY VACCINES MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 21 VETERINARY VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 22 VETERINARY VACCINES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 23 VETERINARY VACCINES MARKET: REGIONAL SNAPSHOT
  • FIGURE 24 INCREASING COMPANION ANIMAL POPULATION AND RISING INCIDENCE OF ZOONOTIC DISEASES TO DRIVE MARKET
  • FIGURE 25 CHINA AND LIVE ATTENUATED VACCINES COMMANDED LARGEST MARKET SHARE IN 2023
  • FIGURE 26 CHINA TO WITNESS HIGHEST CAGR FROM 2024 TO 2029
  • FIGURE 27 VETERINARY VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 28 PET POPULATION IN MAJOR MARKETS IN 2022 (MILLION)
  • FIGURE 29 VETERINARY VACCINES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
  • FIGURE 30 VETERINARY VACCINES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 31 VETERINARY VACCINES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 32 VETERINARY VACCINES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • FIGURE 34 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 35 TOP APPLICANTS/OWNERS (COMPANIES/INSTITUTIONS) FOR VETERINARY VACCINE PATENTS (JANUARY 2014-NOVEMBER 2024)
  • FIGURE 36 AVERAGE SELLING PRICE OF LIVESTOCK VACCINES, BY KEY PLAYER, 2023 (USD)
  • FIGURE 37 AVERAGE SELLING PRICE OF PORCINE VACCINES, BY KEY PLAYER, 2023 (USD)
  • FIGURE 38 VETERINARY VACCINES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 39 VETERINARY VACCINES MARKET: NUMBER OF DEALS AND VALUE OF INVESTMENTS, 2018-2022
  • FIGURE 40 ASIA PACIFIC: VETERINARY VACCINES MARKET SNAPSHOT
  • FIGURE 41 CAT POPULATION ACROSS KEY ASIA PACIFIC COUNTRIES (2024)
  • FIGURE 42 EXPECTED GROWTH IN NUMBER OF VETERINARIANS IN NORTH AMERICA
  • FIGURE 43 NORTH AMERICA: VETERINARY VACCINES MARKET SNAPSHOT
  • FIGURE 44 PET (DOG AND CAT) POPULATION IN US AND CANADA (2022)
  • FIGURE 45 PET (DOG AND CAT) POPULATION IN KEY EUROPEAN COUNTRIES (2022)
  • FIGURE 46 PET (DOG AND CAT) POPULATION IN KEY LATIN AMERICAN COUNTRIES (2022)
  • FIGURE 47 CAT POPULATION IN MIDDLE EASTERN & AFRICAN COUNTRIES (2022)
  • FIGURE 48 VETERINARY VACCINES MARKET: REVENUE ANALYSIS OF TOP FIVE PLAYERS (2019-2023)
  • FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY VACCINES MARKET (2023)
  • FIGURE 50 VETERINARY VACCINES MARKET: RANKING OF KEY MARKET PLAYERS (2023)
  • FIGURE 51 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 52 VETERINARY VACCINES MARKET: COMPANY FOOTPRINT
  • FIGURE 53 VETERINARY VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 54 VETERINARY VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 55 VETERINARY VACCINES MARKET: R&D EXPENDITURE OF KEY PLAYERS (2021-2023)
  • FIGURE 56 EV/EBITDA OF KEY VENDORS
  • FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 58 MERCK & CO., INC.: COMPANY SNAPSHOT
  • FIGURE 59 ZOETIS: COMPANY SNAPSHOT
  • FIGURE 60 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • FIGURE 61 ELANCO: COMPANY SNAPSHOT
  • FIGURE 62 VIRBAC: COMPANY SNAPSHOT
  • FIGURE 63 PHIBRO ANIMAL HEALTH CORPORATION: COMPANY SNAPSHOT
  • FIGURE 64 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT
  • FIGURE 65 NEOGEN CORPORATION: COMPANY SNAPSHOT
  • FIGURE 66 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
  • FIGURE 67 JINYU BIO-TECHNOLOGY CO., LTD.: COMPANY SNAPSHOT
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!